Family Medicine · Year 3 · from Family Medicine
Case 2: Prior Authorization and Patient Advocacy
Patient Case
Patient: Ms. Carmen Rodriguez Age: 58 years old Insurance: Commercial HMO
Clinical Scenario
Ms. Rodriguez is a 58-year-old woman with type 2 diabetes mellitus, currently on maximum-dose metformin and glipizide, with HbA1c of 8.9%. She has tried and failed to tolerate pioglitazone due to edema. Based on her cardiovascular risk profile (hypertension, dyslipidemia, obesity) and inadequate glycemic control, you want to prescribe a GLP-1 receptor agonist (semaglutide), which has demonstrated cardiovascular benefit.
The Prior Authorization Process
Day 1: Initial Prescription
You submit an electronic prescription for semaglutide (Ozempic) 0.25 mg weekly, with titration plan. The pharmacy contacts your office: "Prior authorization required. Coverage denied without PA."
Day 2: Prior Authorization Submission
Your staff submits the prior authorization request including:
- Diagnosis: Type 2 diabetes mellitus, uncontrolled (ICD-10: E11.65)
- Current medications and duration of use
- HbA1c values showing inadequate control
- Contraindication/intolerance to pioglitazone (documented edema)
- Clinical rationale: cardiovascular risk reduction based on ADA guidelines
Day 5: Initial Denial
Denial letter received:
- Reason: "Patient has not tried an SGLT2 inhibitor before GLP-1 agonist"
- Insurance requires step therapy: SGLT2 inhibitor trial before GLP-1 coverage
Clinical Image
Image: Flowchart showing the prior authorization process from initial request through documentation, submission, denial, appeal, peer-to-peer review, and external review options.
Image Source: Wikimedia Commons Attribution: Administrative workflow, Educational Use URL: https://commons.wikimedia.org/wiki/File:Prior_authorization_flow.png
Appeal Process
Day 6: First-Level Internal Appeal
You submit an appeal letter:
Dear Medical Director,
I am writing to appeal the denial of coverage for semaglutide (Ozempic) for my patient, Carmen Rodriguez.
Ms. Rodriguez has type 2 diabetes with HbA1c 8.9% despite maximum-dose metformin (2000 mg daily) and glipizide (20 mg daily) for over 12 months. She has documented intolerance to pioglitazone (peripheral edema requiring discontinuation).
While your step therapy protocol suggests SGLT2 inhibitor trial before GLP-1 agonist, I am requesting an exception based on the following clinical factors:
1. Ms. Rodriguez has stage 3 chronic kidney disease (eGFR 42 mL/min). SGLT2 inhibitors require dose adjustment and have reduced efficacy at this level of renal function.
2. She has a history of recurrent urinary tract infections (3 in the past year). SGLT2 inhibitors increase UTI risk.
3. Per ADA Standards of Care, GLP-1 agonists with proven cardiovascular benefit are recommended for patients with established ASCVD or high cardiovascular risk. Ms. Rodriguez has documented coronary artery disease (prior NSTEMI, 2021).
I am requesting coverage of semaglutide based on medical necessity and published guidelines supporting GLP-1 agonist use in her clinical situation.
Sincerely, [Physician name and credentials]
Day 10: Appeal Denied
Second denial received: "Clinical information reviewed. Original decision upheld."
Peer-to-Peer Review
Day 11: Request Peer-to-Peer Review
You request to speak directly with the insurance company's medical director.
Peer-to-Peer Call:
Insurance Medical Director: "I see the appeal was denied because she hasn't tried an SGLT2 inhibitor."
You: "Thank you for taking my call. I understand your step therapy protocol, but I'd like to discuss why this patient has specific contraindications. She has CKD stage 3 with eGFR of 42 - SGLT2 inhibitors have reduced glycemic efficacy at this level of renal function. More importantly, she has a history of recurrent UTIs, which SGLT2 inhibitors would likely worsen. Additionally, with her cardiovascular history - she had an NSTEMI in 2021 - the ADA specifically recommends GLP-1 agonists with proven cardiovascular benefit like semaglutide."
Insurance Medical Director: "Can you send me her renal function labs and cardiology records documenting the NSTEMI?"
You: "Absolutely. I can have those faxed within the hour."
Day 12: Approval
After review of additional documentation, prior authorization approved for 12 months.
Documentation
Important elements documented in chart:
- Prior authorization process and timeline
- Clinical rationale for medication selection
- Appeals submitted and responses received
- Peer-to-peer conversation details
- Final approval with authorization number
Impact on Patient
Without Advocacy:
- Patient would have been denied evidence-based treatment
- Forced to try medication less appropriate for her clinical situation
- Delay in achieving glycemic and cardiovascular goals
With Advocacy:
- Received appropriate medication for her clinical profile
- Total delay: 12 days (still problematic, but resolved)
- Clinical goals can now be addressed
Teaching Points
- Prior authorization is often necessary but delays care - track denials and appeals to identify patterns
- Documentation is key - include diagnoses, current medications, prior trials/failures, and guideline citations
- Know when to escalate:
- First-level appeal: Written clinical justification
- Peer-to-peer review: Direct physician-to-physician discussion
- External review: Independent third-party review (patient's right)
- Cite evidence-based guidelines (ADA, ACC, etc.) - harder to deny when standard of care is clearly documented
- Document everything - protects the patient and practice, identifies systemic issues
- Advocacy is part of medical practice - the patient cannot navigate this system alone